New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2013
05:55 EDTSHPG, SHPG, SHPG, SHPG, SHPG, SQNM, SQNM, SQNM, SQNM, SQNM, RHHBY, RHHBY, RHHBY, RHHBY, RHHBY, PFE, PFE, PFE, PFE, PFE, PKI, PKI, PKI, PKI, PKI, LMNX, LMNX, LMNX, LMNX, LMNX, ILMN, ILMN, ILMN, ILMN, ILMN, HOLX, HOLX, HOLX, HOLX, HOLX, FLDM, FLDM, FLDM, FLDM, FLDM, GOLD, GOLD, GOLD, GOLD, GOLD, ATHN, ATHN, ATHN, ATHN, ATHN, ALXN, ALXN, ALXN, ALXN, ALXN, AFFY, AFFY, AFFY, AFFY, AFFY, A, A, A, A, AAmerican College of Medical Genetics & Genomics to hold annual meeting
ACMG Annual Clinical Genetics Meeting 2013 is being held in Phoenix, Arizona on March 19-23.
News For A;AFFY;ALXN;ATHN;GOLD;FLDM;HOLX;ILMN;LMNX;PKI;PFE;RHHBY;SQNM;SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
March 20, 2015
10:51 EDTGOLDRandgold downgraded to Reduce from Neutral at Nomura
Subscribe for More Information
10:00 EDTSHPGOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:41 EDTSHPGBernstein global specialty pharma analyst holds analyst/industry conference call
Subscribe for More Information
09:01 EDTRHHBYEli Lilly up 2% to $75.75 in pre-market trading
Subscribe for More Information
08:12 EDTSHPGShire upgraded to Outperform from Market Perform at Bernstein
Bernstein upgraded Shire as the firm thinks that the stock's risk/reward ratio is positive following several new developments. Among these developments are the firm's belief that the company's orphan drug strategy looks increasingly strong, while the risks to the company's Vyvanse and mesalamines drugs look to have moderated and the company has several near-term, 2015 catalysts. Target $295.
07:55 EDTPFEAstraZeneca seen as potential target again if oncology drugs lag, Bloomberg says
Subscribe for More Information
07:41 EDTPFEAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
March 19, 2015
17:39 EDTSQNMSequenom launches the HerediT test in collaboration with Recombine
Sequenom's wholly owned subsidiary, Sequenom Laboratories, and Recombine Inc., a clinical genetic testing company dedicated to helping patients and providers make informed healthcare decisions, launched the HerediT UNIVERSAL carrier screening test as a service to ordering physicians. The HerediT UNIVERSAL test screens for more than 250 genetic diseases by analyzing over 2,000 genetic mutations.
16:14 EDTRHHBYProthena report positive results from Phase 1 study of PRX002
Subscribe for More Information
11:00 EDTPFEPfizer participates in a conference call with Bernstein
Subscribe for More Information
07:59 EDTSQNMSequenom management to meet with William Blair
Subscribe for More Information
07:02 EDTRHHBYSigma-Aldrich signs exclusive distribution agreement with Roche
Subscribe for More Information
06:15 EDTATHNathenahealth coverage transferred with an Outperform at RW Baird
Subscribe for More Information
March 18, 2015
17:09 EDTPFEPfizer CAPiTA published in New England Journal of Medicine
Subscribe for More Information
12:48 EDTRHHBYFly Watch: Biogen predicted to report strong Alzheimer's data this Friday
Subscribe for More Information
08:33 EDTILMNTrovagene appoints Matthew Posard as Chief Commercial Officer
Subscribe for More Information
08:31 EDTAAgilent names president and COO Mike McMullen as CEO
Subscribe for More Information
08:03 EDTSHPGTherapeuticsMD names Angus Russell, J. Martin Carroll as directors
TherapeuticsMD (TXMD) announced the appointment of two biopharmaceutical senior executives, Angus C. Russell and J. Martin Carroll, as independent members of its board of directors, and that Randall S. Stanicky has stepped down from the board of directors. Angus C. Russell served as CEO of Shire PLC (SHPG) from June 2008 until April 2013. J. Martin Carroll served as president and CEO of Boehringer Ingelheim Corp. U.S. from 2003 until 2011.
07:46 EDTRHHBYLilly Roche would have upbeat read through from strong BIIB data, says Bernstein
Bernstein notes that the data for Biogen's (BIIB) Alzheimer's treatment, due to be released on Friday, is widely expected to be positive. The firm thinks that positive data would boost the outlook for similar Alzheimer's drugs being developed by Eli Lilly (LLY) and Roche (RHHBY), since consensus estimates for those drugs are low. The firm keeps Outperform ratings on Eli Lilly and Roche.
07:22 EDTSHPGShire looking for 'transformational' deal, Betaville blog says
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use